Results 51 to 60 of about 12,625 (176)

The ‘Health Collapse Spiral’: A 35‐Month Longitudinal Case Study of Physiological Reserve Depletion in a Centenarian Following COVID‐19

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT This 35‐month case report documents irreversible physiological reserve depletion in a centenarian multimorbid man after COVID‐19. Prior to infection, he maintained precarious homeostasis for 17 years despite severe frailty (CFS 7), with stable CKD stage 3a (eGFR 58.3 mL/min/1.73 m2) and albumin 36.2 g/L.
Shan Xu, Wei Zhang, Qiaoxiang Yin, Jie Wei, Yanmin Ma, Wenwen Jia   +5 more
wiley   +1 more source

VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

, 2023
To the Editor: Cao and colleagues (Feb. 2 issue)1 report that the oral antiviral agent VV116 was noninferior to nirmatrelvir–ritonavir in alleviating Covid-19–related ...
Lin, Dan-Yu, Fleming, Thomas R
core   +1 more source

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use

, 2022
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and conflict of interest H. A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of ...
Hannah A. Blair (13864794)
core   +1 more source

Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT QT interval prolongation associated with drug administration is an important consideration in drug development. Patients with COVID‐19 are at increased risk for cardiac complications, and QT interval prolongation correlates with higher mortality.
Chi‐Chi Peng, Ran Duan, Mazin Abdelghany, Santosh Davies, Deqing Xiao, Anna Kwan, Ana Ruiz‐Garcia   +6 more
wiley   +1 more source

Complete Heart Block Triggered by Nirmatrelvir-Ritonavir and Verapamil. [PDF]

JACC Case Rep
Ritonavir-boosted nirmatrelvir (Paxlovid) is a treatment for COVID-19. However, ritonavir, a cytochrome P450 (CYP) CYP3A4 inhibitor, poses a risk of significant drug-drug interactions.
Offord E, Nabi M, Mankbadi M, Marchetta A, Rosenthal L.   +4 more
europepmc   +2 more sources

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Severe Occupational Hypersensitivity Pneumonitis: A Case Series of Four Patients Requiring Lung Transplantation

American Journal of Industrial Medicine, Volume 69, Issue 5, Page 323-334, May 2026.
ABSTRACT Hypersensitivity pneumonitis (HP) is an immune‐mediated interstitial lung disease triggered by repeated inhalation of organic or chemical antigens. Occupational exposures account for approximately 19% of all cases. Early diagnosis, identification of the responsible antigen(s), and immediate avoidance of exposure are crucial to prevent ...
Ludwig Frei‐Stuber, Judith Mohren, Ester Mau, Bernhard Werner, Rudolf A. Hatz, Jürgen Barton, Dennis Nowak   +6 more
wiley   +1 more source

A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.

PLoS ONE, 2023
BackgroundLarge observational studies have demonstrated the real-world effectiveness of nirmatrelvir-ritonavir in preventing severe COVID-19 in higher risk individuals, but have provided limited information on other aspects of nirmatrelvir-ritonavir use.
Valerie Leung, Suzanne Gill, Andrea Llanes, Armughan Khawaja, Amanda Stagg, Janine McCready, Mariana Jacubovich, Grace Ho, Jeff Powis, Christopher Kandel   +9 more
doaj   +1 more source

Evaluation of a Protocol Managing the Cyclosporine and Nirmatrelvir/Ritonavir Interaction in Kidney Transplant Recipients. [PDF]

Kidney360
Pharmacy residents have the opportunity to complete a research project during their residency training, which provides them with skills on how to conduct and manage a research project.
Agtarap K, Giguère P, Deschênes MJ, DeVreese L, McDougall J, Hoar S, Hiremath S.   +6 more
europepmc   +2 more sources

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo, Alan Y. Hsu, De‐Yi Liu, Bing‐Qi Wu, James Cheng‐Chung Wei, Ning‐Yi Hsia, Yi‐Ching Shao, Chun‐Ting Lai, Chun‐Chi Chiang, Chun‐Ju Lin, Huan‐Sheng Chen, Yu‐Hsun Wang, Hsin Tseng, Ho‐Che Hsu, Yi‐Yu Tsai   +14 more
wiley   +1 more source